Arcutis (ARQT) Director Uses 10b5-1 Plan to Sell 10,000 Shares
Rhea-AI Filing Summary
Arcutis Biotherapeutics director Howard G. Welgus executed planned transactions under a 10b5-1 trading plan on 09/02/2025. He exercised a fully vested stock option with a $1.6806 exercise price to acquire 10,000 shares and concurrently sold 10,000 common shares at a weighted average price of $15.6383, with sale prices ranging from $15.45 to $15.81. After these transactions he beneficially owned 100,206 shares. The 10b5-1 plan was adopted March 11, 2025, and runs through May 29, 2026.
Positive
- Transactions executed under a documented 10b5-1 trading plan
- Option exercised is fully vested
- Form discloses weighted average sale price and range
Negative
- Director sold 10,000 shares, reducing direct holdings
Insights
TL;DR: Director exercised a vested option then sold the same number of shares under a 10b5-1 plan; ownership modestly adjusted.
The Form 4 discloses a paired transaction: a stock option exercise (10,000 shares at $1.6806) and the sale of 10,000 common shares at a weighted average of $15.6383. The sales were effected pursuant to a 10b5-1 plan adopted on March 11, 2025. The option is fully vested and the post-transaction beneficial ownership is 100,206 shares. For investors, this is a routine insider liquidity event executed under a pre-established plan; no additional company operational metrics are disclosed in this filing.
TL;DR: Use of a documented 10b5-1 plan and attorney-in-fact signature indicates procedural compliance.
The filing explicitly states the transactions were made pursuant to a 10b5-1 trading plan with a specified adoption and end date, and the Form 4 is signed by an attorney-in-fact. The report identifies the reporting person as a director and notes the option exercised is fully vested. The disclosure is concise and focused on ownership changes; there are no indications of amendments or incomplete reporting within the provided content.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $0.00 | -- |
| Sale | Common Stock | 10,000 | $15.6383 | $156K |
Footnotes (1)
- The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.45 to $15.81, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This option is fully vested.
